<?xml version="1.0" encoding="UTF-8"?>
<p>Dysexecutive profile, which is known as the most predominant component of cognitive deficits in PD-MCI and PDD, has been substantiated to be improved with levodopa treatment [
 <xref rid="B6" ref-type="bibr">6</xref>, 
 <xref rid="B93" ref-type="bibr">93</xref>]. Levodopa was found to act on some aspects of cognition such as flexibility and working memory without beneficial changes of other functions like visuospatial recognition, verbal ability, or associative learning [
 <xref rid="B6" ref-type="bibr">6</xref>, 
 <xref rid="B93" ref-type="bibr">93</xref>]. For patients with nondopaminergic antiparkinsonian administration, antagonists of the NMDA-type glutamate receptor, amantadine, for instance, could slow down the progressive transition from PD-MCI to PDD, via increasing dopamine release and blocking dopamine reuptake [
 <xref rid="B109" ref-type="bibr">108</xref>].
</p>
